Table 5. Odds Ratios for Future CAD Events by CCL2 polymorphism of study participants.
P* | p† | p‡ | |||
---|---|---|---|---|---|
−2835 C/A | |||||
AA (ref) – CA – CC | 1.00 (0.72 to 1.39) | 0.90 (0.65 to 1.24) | 0.429 | 0.129 | 0.352 |
AA vs CA + CC | 0.94 (0.69 to 1.29) | 0.711 | 0.184 | 0.485 | |
CC vs CA + AA | 0.90 (0.76 to 1.06) | 0.193 | 0.064 | 0.157 | |
−2578 A/G | |||||
GG (ref) – GA – AA | 1.03 (0.75 to 1.42) | 0.93 (0.68 to 1.27) | 0.448 | 0.209 | 0.437 |
GG vs GA + AA | 0.97 (0.71 to 1.32) | 0.854 | 0.267 | 0.552 | |
AA vs GA + GG | 0.90 (0.77 to 1.01) | 0.210 | 0.100 | 0.898 | |
−2136 A/T | |||||
AA (ref) – AT – TT | 1.05 (0.88 to 1.25) | 0.89 (0.59 to 1.33) | 0.720 | 0.498 | 0.652 |
AA vs AT + TT | 1.02 (0.86 to 1.21) | 0.795 | 0.527 | 0.568 | |
TT vs AT + AA | 0.88 (0.58 to 1.31) | 0.517 | 0.459 | 0.897 | |
−1811 A/G | |||||
AG vs GG | 1.20 (0.90 to 1.60) | 0.222 | 0.076 | 0.071 | |
−927 G/C | |||||
GG (ref) – GC – CC | 0.92 (0.77 to 1.10) | 0.87 (0.56 to 1.29) | 0.549 | 0.559 | 0.499 |
GG vs GC + CC | 0.91 (0.77 to 1.08) | 0.288 | 0.934 | 0.309 | |
CC vs GC + GG | 0.90 (0.61 to 1.32) | 0.575 | 0.332 | 0.338 | |
+764 C/G | |||||
CC (ref) – CG – GG | 1.06 (0.89 to 1.26) | 0.91 (0.60 to 1.40) | 0.725 | 0.499 | 0.570 |
CC vs CG + GG | 1.04 (0.88 to 1.23) | 0.648 | 0.410 | 0.436 | |
GG vs CG + CC | 0.90 (0.59 to 1.37) | 0.619 | 0.577 | 0.903 | |
+3726 T/C | |||||
TT (ref) – TC – CC | 0.97 (0.81 to 1.16) | 1.29 (1.01 to 1.66) | 0.064 | 0.254 | 0.083 |
TT vs TC + CC | 1.04 (0.88 to 1.23) | 0.635 | 0.594 | 0.474 | |
CC vs TC + TT | 1.31 (1.05 to 1.65) | 0.020 | 0.098 | 0.026 |
Odds ratios and the corresponding 95% confidence interval calculated by conditional logistic regression, taking into account matching for age, gender, and enrollment time per CCL2 polymorphism.
P = Unadjusted p value.
P = p value adjusted for body mass index, waist circumference, systolic blood pressure and triglycerides;
P = p value adjusted for the Framingham Risk Score.